Related Experiment Video

Updated: May 12, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Nutrient-Stimulated Hormone Therapies in Heart Failure: Targeting Cardiometabolic Burden Beyond Weight Reduction

Dong-Hyuk Cho1

  • 1Division of Cardiology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

International Journal of Heart Failure
|May 11, 2026
PubMed

Insights

Nutrient-Stimulated Hormone (NuSH) therapies, like GLP-1 agonists, offer significant weight loss and heart protection for obesity and heart failure (HF). These therapies are becoming essential for managing HFpEF and require careful use in HFrEF.

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Obesity and heart failure (HF) form a growing epidemic with a unique cardiometabolic profile.
  • Traditional treatments like lifestyle changes and bariatric surgery have limitations in managing this complex condition.
  • Nutrient-Stimulated Hormone (NuSH) therapies, including glucagon-like peptide-1 receptor agonists, represent a novel therapeutic avenue.

Purpose of the Study:

  • To review the paradigm shift in managing obesity and HF with NuSH therapies.
  • To analyze the impact of NuSH therapies on heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF).
  • To discuss future directions for NuSH therapy optimization in cardiovascular care.

Main Methods:

  • Review of pivotal clinical trial evidence, including STEP-HFpEF and SUMMIT.
  • Analysis of the mechanisms of action and clinical outcomes associated with NuSH therapies.
  • Discussion of safety considerations and future research needs.

Main Results:

  • NuSH therapies provide surgical-magnitude weight loss and significant cardioprotection.
  • Established as a new standard of care for HFpEF, improving functional capacity and reducing clinical endpoints.
  • NuSH therapies show promise but require a cautious, precision-based approach in HFrEF due to safety concerns.

Conclusions:

  • NuSH therapies are evolving into essential disease-modifying agents for HF management.
  • Clinical practice requires recalibration to address the metabolic underpinnings of HF.
  • Future research should focus on mitigating sarcopenic obesity and utilizing biomarker-guided protocols.

Keywords:
Heart failureNutrient-stimulating hormone-based therapiesObesity

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...